Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat rare and orphan autoimmune and inflammatory diseases. Its lead drug candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome. The company is based in New York, New York. Akari Therapeutics, Plc is a subsidiary of RPC Pharma Limited.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AKTX
CUSIPN/A
Phone44-20-8004-0270
Debt
Debt-to-Equity RatioN/A
Current Ratio3.19
Quick Ratio2.38
Price-To-Earnings
Trailing P/E Ratio-7.18
Forward P/E Ratio-1.57
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.70 per share
Price / Book1.18
Profitability
EPS (Most Recent Fiscal Year)($0.28)
Net Income$-32,570,000.00
Net MarginsN/A
Return on Equity-187.46%
Return on Assets-122.21%
Miscellaneous
Employees15
Outstanding Shares11,780,000
Akari Therapeutics (NASDAQ:AKTX) Frequently Asked Questions
What is Akari Therapeutics' stock symbol?
Akari Therapeutics trades on the NASDAQ under the ticker symbol "AKTX."
When is Akari Therapeutics' next earnings date?
What price target have analysts set for AKTX?
4 equities research analysts have issued 1 year price targets for Akari Therapeutics' stock. Their forecasts range from $2.50 to $8.00. On average, they anticipate Akari Therapeutics' share price to reach $4.50 in the next year. View Analyst Ratings for Akari Therapeutics.
What are Wall Street analysts saying about Akari Therapeutics stock?
Here are some recent quotes from research analysts about Akari Therapeutics stock:
- 1. According to Zacks Investment Research, "Akari Therapeutics PLC is a biopharmaceutical company. It focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. The Company's lead drug consist of Coversin is a recombinant small protein, which acts on complement component-C5, preventing release of C5a and formation of C5b-9. Akari Therapeutics PLC, formerly known as Celsus Therapeutics Plc, is based in London, United Kingdom. " (1/16/2018)
- 2. Canaccord Genuity analysts commented, "Date and time of first dissemination: September 21, 2017, 23:12 ET Date and time of production: September 21, 2017, 20:41 ET Target Price / Valuation Methodology: Impax Laboratories – IPXL Our $19 price target is derived from a blend of DCF (7.7% WACC, +1% terminal growth) and a 9.2x forward EV/EBITDA on our 2018 estimates. IPXL shares currently trade around 8x our 2018 EV/EBITDA compared to a group average of around 9.2x. We think a group average EV/EBITDA valuation is warranted because of potential P&L leverage growing profitability faster than revenue which warrants a premium, a premium warranted for the company’s well-respected leadership offset by a discount to the group for relatively low expected top-line growth and a low-duration FTF/FTM based generics pipeline." (9/22/2017)
Who are some of Akari Therapeutics' key competitors?
Some companies that are related to Akari Therapeutics include Juniper Pharmaceuticals (JNP), Checkpoint Therapeutics (CKPT), Cumberland Pharmaceuticals (CPIX), Arcturus Therapeutics (ARCT), KemPharm (KMPH), Genprex (GNPX), Advaxis (ADXS), Medicure Inc. Common Stock (MCUJF), VIVUS (VVUS), Evofem Biosciences (EVFM), Versartis (VSAR), Kalvista Pharmaceuticals (KALV), GT Biopharma (GTBP), Vascular Biogenics (VBLT) and SCYNEXIS (SCYX).
Who are Akari Therapeutics' key executives?
Akari Therapeutics' management team includes the folowing people:
- Dr. Ray Prudo M.D., Exec. Chairman (Age 73)
- Mr. Clive Richardson, Chief Operations Officer, Director & Interim CEO (Age 53)
- Mr. Dov Elefant, Chief Financial Officer (Age 51)
- Dr. Miles Nunn, Chief Scientific Officer
- Dr. Wynne Weston-Davies MRCS, LRCP, MBBS, FRCS, ECFMG, Medical Director
Has Akari Therapeutics been receiving favorable news coverage?
Media headlines about AKTX stock have trended somewhat positive on Thursday, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Akari Therapeutics earned a news impact score of 0.19 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 46.86 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
Who are Akari Therapeutics' major shareholders?
Which institutional investors are selling Akari Therapeutics stock?
Which institutional investors are buying Akari Therapeutics stock?
How do I buy shares of Akari Therapeutics?
Shares of AKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Akari Therapeutics' stock price today?
One share of AKTX stock can currently be purchased for approximately $2.00.
How big of a company is Akari Therapeutics?
Akari Therapeutics has a market capitalization of $24.38 million. The biopharmaceutical company earns $-32,570,000.00 in net income (profit) each year or ($0.28) on an earnings per share basis. Akari Therapeutics employs 15 workers across the globe.
How can I contact Akari Therapeutics?
Akari Therapeutics' mailing address is 75/76 WIMPOLE STREET, LONDON X0, W1G 9RT. The biopharmaceutical company can be reached via phone at 44-20-8004-0270 or via email at [email protected]
MarketBeat Community Rating for Akari Therapeutics (AKTX)
MarketBeat's community ratings are surveys of what our community members think about Akari Therapeutics and other stocks. Vote "Outperform" if you believe AKTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
